Furthermore, while ITGB4 is almost absent in the TCs of primary prostate cancer specimens, the percentage of ITGB4+ TCs drastically increases in locally advanced/recurrent tumors (treated with palliative transurethral resection, TURp), lymph node and distant metastases (Fig. 10C). This evidence concerns the gene ITGB4 and prostate cancer.